Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents
Antineoplastic agents are currently being administered through catheters placed intraperitoneally to treat cancer localized to the peritoneum. This route allows for high local concentrations of antineoplastic drug at the tumor site with low levels of the drug systemically, thereby reducing the systemic toxicity. However, there are complications with this mode of delivery, including a decrease in catheter patency and induction of adhesion formation, which leads to decreased drug dispersion and limits continuing drug administration. A model was developed in rats to mimic this method of antineoplastic drug administration that produced fibrin deposition around the catheter and adhesion formation invoving bowel, intestines and liver. All antineoplastic agents tested, including Adriamycin, methothexate, bleomycin, mitoxantrone and cisplatin, induced moderate to severe adhesion formation with varying effects on catheter patency. When an intraperitoneal bolus of tometin encapsulted in liposomes was tested with Adriamycin delivered via an osmotic minipump, a reduction in adhesion formation was observed. However, highly significant adhesion reduction was found when tolmetin was coadministered with the antitumor agents.
KeywordsBleomycin Adriamycin Mitoxantrone Adhesion Formation Antineoplastic Agent
Unable to display preview. Download preview PDF.
- 1.Casper ES, Kelsen DP, Alcock NW, Lewis JL (1983) Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with iv route. Cancer Treat Rep 67: 235Google Scholar
- 2.Hacker NF, Berek JS, Pretorius G, Zuckerman J, Eisenkop S, Lagasse LD (1987) Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer. Obstet Gynecol 70: 759Google Scholar
- 3.Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845Google Scholar
- 4.Lucas WE, Markman M, Howell SB (1985) Intraperitoneal chemotherapy for advanced ovarian cancer. Am J Obstet Gynecol 152: 474Google Scholar
- 5.Markman M, Cleary S, Pfeifle CE, Howell SB (1985) High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity. Cancer 56: 2364Google Scholar
- 6.Markman M, Vasilev S, Howell SB, diZerega GS (1986) Anticancer adhesions+ibuprofen inhibition of peritoneal cavity fibrin deposition induced by intraperitoneal administration of cisplatin plus cytorabine. Clin Res 34: 5674Google Scholar
- 7.Myers C (1984) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol 11: 275Google Scholar
- 8.Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, Young RC (1979) Chemotherapy for murine ovarian cancer: a rationale for Ip therapy with adriamycin. Cancer 63: 269Google Scholar
- 9.Rodgers KE, Ellefson DD, Girgis W, Scott L, diZerega GS (1988) Effects of tolmetin sodium dihydrate on normal and postsurgical peritoneal cell function. Int J Immunopharmacol 10: 111Google Scholar
- 10.Rodgers K, Bracken K, Richer L, Girgis W, diZerega GS (1989). Inhibition of postsurgical adhesions by liposomes containing nonsteroidal anti-inflammatory drugs. Int J Fertil 33: 315Google Scholar